Aptahem's vision is to deliver best in class RNA-based drugs for sepsis and other severe inflammatory conditions, thereby saving patients’ lives and improving treatment options.
Aptahem’s business strategy is to perform active business development activities to identify future collaboration partners by frequently interact, present and discuss the company’s development status with pharmaceutical and biotechnology companies that have commercial synergies with Aptahem’s technology. The aim with these activities is to enter into a successful partnering or licence deal to generate resources to promote Aptahem’s portfolio of pharmaceutical candidates and to increase the company’s value. Aptahem’s aim is to enter into such an agreement for the drug candidate Apta-1 in early clinical phase.
Apta-1 as a new potential treatment for sepsis
Sepsis is a global, challenging and deadly health problem causing a considerable economic burden and extensive unmet clinical needs worldwide.
Up to date, there is no available cure to treat sepsis.
Aptahem’s novel drug candidate Apta-1 is an RNA aptamer that, by interacting with at least three important factors for sepsis, such as coagulation, inflammation and tissue repair, can be the sought-after solution for sepsis and other acute inflammatory conditions.